New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 13, 2012
10:24 EDTAMT, ABC, CELG, ITW, NOK, PPL, JBHTOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Tower (AMT) downgraded to Neutral from Overweight at Piper Jaffray... AmerisourceBergen (ABC) downgraded to Equal Weight from Overweight at Morgan Stanley... Celgene (CELG) downgraded to Hold from Buy at Auriga... Illinois Tool Works (ITW) downgraded to Underweight from Equal Weight at Morgan Stanley... Nokia (NOK) downgraded to Equal Weight from Overweight at Barclays... PPL Corp. (PPL) downgraded to Buy from Conviction Buy at Goldman... J.B. Hunt (JBHT) downgraded to Neutral from Buy at Sterne Agee.
News For AMT;ABC;CELG;ITW;NOK;PPL;JBHT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 22, 2014
06:39 EDTNOKMicrosoft Lumia to replace Nokia brand, The Verge reports
Microsoft plans to make Microsoft Lumia the new brand name that takes the place of Nokia for the software maker, reports The Verge. Nokia still exists as a separate company without its phones business, focusing on mapping and network infrastructure. Reference Link
October 21, 2014
09:23 EDTCELGCelgene GED-0301 said to have 67% 12-week remission at high dose in trial
Subscribe for More Information
08:07 EDTITWIllinois Tool Works raises FY14 EPS view to $4.57-$4.65 from $4.50-$4.62
Subscribe for More Information
08:07 EDTITWIllinois Tool Works sees Q4 EPS $1.07-$1.15, consensus $1.13
Sees Q4 revenue flat due to currency translation effects, consensus $3.64B.
08:04 EDTITWIllinois Tool Works reports Q3 EPS $1.28, consensus $1.23
Subscribe for More Information
October 20, 2014
15:36 EDTITWNotable companies reporting before tomorrow's open
Subscribe for More Information
13:26 EDTCELGCelgene I&I franchise boosted by Crohn’s trial data, says William Blair
William Blair said it views the preliminary Phase II efficacy and safety data from mongersen in Crohn’s disease reported by Celgene as encouraging. The firm noted that the 10 mg arm did not achieve significance, but the three data points collectively formed a robust dose-response that William Blair said lends support for the drug's proposed mechanism of action. William Blair believes mongersen complements Celgene’s Inflammation & Immunology portfolio and the firm maintains its Outperform rating on the stock, which is up 4% to $91.65 in afternoon trading.
13:21 EDTCELGCelgene reports Phase II data in Crohn’s Disease to be presented at UEG
Subscribe for More Information
October 17, 2014
13:18 EDTCELGLeerink's biotech analyst holds an analyst/industry conference call
Subscribe for More Information
10:00 EDTABCOn The Fly: Analyst Initiation Summary
Subscribe for More Information
October 16, 2014
16:20 EDTABCMcKesson initiated with an Outperform at RBC Capital
Subscribe for More Information
16:17 EDTABCAmerisourceBergen initiated with an Outperform at RBC Capital
Target $88.
15:10 EDTCELGAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
October 14, 2014
08:36 EDTJBHTJ.B. Hunt reports Q3 dedicated contract services revenue $361M
Subscribe for More Information
08:34 EDTJBHTJ.B. Hunt reports Q3 EPS 87c, consensus 84c
Subscribe for More Information
October 13, 2014
15:08 EDTJBHTJ.B. Hunt technical comments before earnings
Subscribe for More Information
October 10, 2014
10:15 EDTNOKNokia, China Mobile sign framework agreement valued at $970M
Subscribe for More Information
08:41 EDTCELGCelgene reports apremilast significantly improved preexisting psoriasis in study
Subscribe for More Information
08:39 EDTCELGCelgene says data show Apremilast treatment resulted in improved quality of life
Subscribe for More Information
October 9, 2014
07:13 EDTNOKNokia reinstated with a Buy at BofA/Merrill
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use